

Update from NRS Reproductive Health and Childbirth Specialty Group September 2021



Bell heather, *Erica cinerea*



NIHR Associate Principal Investigator (API) scheme has now gone live for Reproductive Health and Childbirth

The web page and associated forms have all been updated. The API team is planning to have a launch event in November, we will keep you updated.

The API Scheme aims to develop junior doctors, nurses and allied health professionals to become the PIs of the future and provides formal recognition of a trainee's engagement in NIHR Portfolio research studies through the conferment of Associate PI status endorsed by the NIHR and medical Royal Colleges which include The Royal College of Obstetricians and Gynaecologists.

<https://www.nihr.ac.uk/documents/associate-principal-investigator-pi-scheme/25040>



CHIEF
SCIENTIST
OFFICE

NRS Career Researcher Fellowships

Open for applications – Deadline Wednesday 17th November 2021



The award provides funding for protected time (2 sessions) to contribute to, conduct and lead clinical research. The aim is to strengthen the research culture in the NHS and to increase capacity in areas that are either aligned to research excellence locally or nationally or areas where the potential exists to develop research excellence. <https://www.cso.scot.nhs.uk/nrsfellowshipsround11/>

For more information, guidance and application forms please see the [NRS Fellowship page](https://www.cso.scot.nhs.uk/personal-awards-initiative/nrs-career-researcher-fellowships/).
<https://www.cso.scot.nhs.uk/personal-awards-initiative/nrs-career-researcher-fellowships/>

Applications should be emailed to CSOFellowshipapplication@gov.scot by 5pm Wed 17th November 2021

Health Research Authority Communication on new student eligibility criteria



In March 2020 student research approvals were paused to create capacity for urgent COVID-19 research. From 1st September 2021 the new [student eligibility criteria](https://www.hra.nhs.uk/planning-and-improving-research/research-planning/student-research/#september) will come into force, introducing new eligibility criteria for stand-alone student research, designed to ensure that students' experience of research reflects how modern health and social care research is conducted. <https://www.hra.nhs.uk/planning-and-improving-research/research-planning/student-research/#september>

The [student research tool kit](https://www.hra.nhs.uk/planning-and-improving-research/research-planning/student-research/) shows the type of stand-alone research projects which students will be able to undertake. Please visit the [website](https://www.hra.nhs.uk/planning-and-improving-research/research-planning/student-research/) for full details <https://www.hra.nhs.uk/planning-and-improving-research/research-planning/student-research/>.

Please send your Good News, queries or any feedback to:
Abha (abha.maheshwari@abdn.ac.uk), NRS Clinical Research Lead, or
Txaro (maria.amezaga@nhs.scot), NRS Champion Support Manager

GOOD NEWS STORIES

'Long-awaited' research into effects of long-term health conditions on expectant mums and their babies underway



Multimorbidity and Pregnancy: Determinants, Clusters, Consequences and Trajectories (MuM-PreDiCT).

The impact of having more than one long-term health condition on pregnant mothers and their babies is to be investigated by researchers at the University of Aberdeen. Dr Mairead Black is co-leading the Aberdeen side of the project alongside Professor Louise Locock. Full details [here](#).

This new three year UK-wide study funded by UK Research and Innovation (UKRI) Strategic Priorities Fund (SPF) is led by the University of Birmingham in collaboration with the University of Aberdeen and University of St Andrews in Scotland, and further universities and NHS Trusts across the UK.

See University of Birmingham release [here](#).



THE GBS3 TRIAL NEEDS YOU!

GBS3. Routine testing for Group B Streptococcus. CPMS ID 42782, IRAS 2636.

Chief Investigator: Professor Jane Daniels, University of Nottingham. Funder: NIHR.

The GBS3 team is delighted to let you know that following a pandemic induced pause between November 2020 and April 2021, the GBS3 Trial is now well underway. We have now randomised 14 sites and four more will be randomised this month. Sites taking part are randomised to one of three strategies - routine antenatal ECM (Enriched Culture Medium) testing for GBS, routine intrapartum rapid testing for GBS or - the control - Risk Factor group which continues with usual care based on the RCOG GTG 36 which advocates only women identified as high risk for their babies developing early onset GBS are tested and/or offered antibiotics in labour. Full regulatory approvals for Scotland should be in place soon and we will be able to start randomising Scottish sites.

We would love more Scottish sites to come on board. If your annual birth rate is over 2500 and you would like to take part in this important trial then please contact our team GBS3@nottingham.ac.uk to start the conversation.

The GBS3 team is waiting to hear from you!

UK centres needed for APOSTEL-8 trial. Up to date information

APOSTEL-8. Atosiban versus placebo in the treatment of threatened preterm birth.

CPMS ID 35308, IRAS 230066. Funder: Netherlands Organization for Health Research and Development.

The aim of this study is to investigate if tocolysis with atosiban in late preterm birth (30 to 34 weeks) is effective compared with placebo in improving neonatal morbidity and mortality.

Nottingham University Hospitals NHS Trust has recently obtained NIHR Research for Patient Benefit funding to support UK recruitment to this trial. There is £4000 available for a research fridge and a £37/participant payment.

This UK recruitment is led by Professor Kate Walker, Associate Professor of Obstetrics, Nottingham University.

Please see [Summary and detailed presentation](#).

So far just have Nottingham University Hospitals Trust up and running, NHS Lothian starting soon, have 5 sites in set-up. Need 20 UK sites total! Please let us know if you or your colleagues are interested in participating.

**APO
STEL
L # 8**

REPRODUCTIVE HEALTH & CHILDBIRTH STUDIES. PORTFOLIO UPDATE.

Please find [here](#) Eligible Studies Active in Scotland, data cut 07/09/2021. Eligible studies are supported by a funder which appears on the [CSO Eligible Funders list](#). For study information or any queries please contact Abha or Txaro.